Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3.
Harikrishnan, L.S., Kamau, M.G., Wan, H., Inghrim, J.A., Zimmermann, K., Sang, X., Mastalerz, H.A., Johnson, W.L., Zhang, G., Lombardo, L.J., Poss, M.A., Trainor, G.L., Tokarski, J.S., Lorenzi, M.V., You, D., Gottardis, M.M., Baldwin, K.F., Lippy, J., Nirschl, D.S., Qiu, R., Miller, A.V., Khan, J., Sack, J.S., Purandare, A.V.(2011) Bioorg Med Chem Lett 21: 1425-1428
- PubMed: 21282055 
- DOI: https://doi.org/10.1016/j.bmcl.2011.01.022
- Primary Citation of Related Structures:  
3Q32 - PubMed Abstract: 
SAR studies of pyrrolo[1,2-f]triazines as JAK2 inhibitors is presented. Achieving JAK2 inhibition selectively over JAK3 is discussed.
Organizational Affiliation: 
Bristol-Myers Squibb Co., Princeton, NJ 08543-4000, USA. lalgudi.harikrishnan@bms.com